vs
ProFrac Holding Corp.（ACDC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是ProFrac Holding Corp.的1.8倍（$772.1M vs $436.5M），Revvity净利率更高（12.7% vs -33.2%，领先45.9%），Revvity同比增速更快（5.9% vs -4.0%），Revvity自由现金流更多（$161.8M vs $12.9M），过去两年Revvity的营收复合增速更高（9.0% vs -13.4%）
ProFrac Holding Corp.是一家领先的北美能源服务企业，主要为油气勘探开采企业提供水力压裂、完井及相关配套服务，核心客户覆盖美国、加拿大主要陆上页岩及常规油气产区的上游运营商。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ACDC vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.8倍
$436.5M
营收增速更快
RVTY
高出9.9%
-4.0%
净利率更高
RVTY
高出45.9%
-33.2%
自由现金流更多
RVTY
多$148.9M
$12.9M
两年增速更快
RVTY
近两年复合增速
-13.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $436.5M | $772.1M |
| 净利润 | $-144.7M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | -24.9% | 14.5% |
| 净利率 | -33.2% | 12.7% |
| 营收同比 | -4.0% | 5.9% |
| 净利润同比 | -37.8% | 3.9% |
| 每股收益（稀释后） | $-0.83 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACDCRVTY
| Q4 25 | $436.5M | $772.1M | ||
| Q3 25 | $403.1M | $698.9M | ||
| Q2 25 | $501.9M | $720.3M | ||
| Q1 25 | $600.3M | $664.8M | ||
| Q4 24 | $454.7M | $729.4M | ||
| Q3 24 | $575.3M | $684.0M | ||
| Q2 24 | $579.4M | $691.7M | ||
| Q1 24 | $581.5M | $649.9M |
净利润ACDCRVTY
| Q4 25 | $-144.7M | $98.4M | ||
| Q3 25 | $-100.9M | $46.7M | ||
| Q2 25 | $-105.9M | $53.9M | ||
| Q1 25 | $-17.5M | $42.2M | ||
| Q4 24 | $-105.0M | $94.6M | ||
| Q3 24 | $-45.2M | $94.4M | ||
| Q2 24 | $-66.7M | $55.4M | ||
| Q1 24 | $1.8M | $26.0M |
毛利率ACDCRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率ACDCRVTY
| Q4 25 | -24.9% | 14.5% | ||
| Q3 25 | -19.5% | 11.7% | ||
| Q2 25 | -10.8% | 12.6% | ||
| Q1 25 | 2.7% | 10.9% | ||
| Q4 24 | -10.3% | 16.3% | ||
| Q3 24 | -0.7% | 14.3% | ||
| Q2 24 | -8.5% | 12.4% | ||
| Q1 24 | 6.9% | 6.8% |
净利率ACDCRVTY
| Q4 25 | -33.2% | 12.7% | ||
| Q3 25 | -25.0% | 6.7% | ||
| Q2 25 | -21.1% | 7.5% | ||
| Q1 25 | -2.9% | 6.4% | ||
| Q4 24 | -23.1% | 13.0% | ||
| Q3 24 | -7.9% | 13.8% | ||
| Q2 24 | -11.5% | 8.0% | ||
| Q1 24 | 0.3% | 4.0% |
每股收益（稀释后）ACDCRVTY
| Q4 25 | $-0.83 | $0.86 | ||
| Q3 25 | $-0.60 | $0.40 | ||
| Q2 25 | $-0.67 | $0.46 | ||
| Q1 25 | $-0.12 | $0.35 | ||
| Q4 24 | $-0.67 | $0.77 | ||
| Q3 24 | $-0.29 | $0.77 | ||
| Q2 24 | $-0.42 | $0.45 | ||
| Q1 24 | $0.00 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $22.9M | $919.9M |
| 总债务越低越好 | $832.7M | — |
| 股东权益账面价值 | $717.5M | $7.3B |
| 总资产 | $2.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.16× | — |
8季度趋势，按日历期对齐
现金及短期投资ACDCRVTY
| Q4 25 | $22.9M | $919.9M | ||
| Q3 25 | $58.0M | $931.4M | ||
| Q2 25 | $26.0M | $991.8M | ||
| Q1 25 | $16.0M | $1.1B | ||
| Q4 24 | $14.8M | $1.2B | ||
| Q3 24 | $25.5M | $1.2B | ||
| Q2 24 | $24.0M | $2.0B | ||
| Q1 24 | $28.3M | $1.7B |
总债务ACDCRVTY
| Q4 25 | $832.7M | — | ||
| Q3 25 | $907.0M | — | ||
| Q2 25 | $941.9M | — | ||
| Q1 25 | $967.9M | — | ||
| Q4 24 | $936.1M | — | ||
| Q3 24 | $986.7M | — | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $895.1M | — |
股东权益ACDCRVTY
| Q4 25 | $717.5M | $7.3B | ||
| Q3 25 | $862.0M | $7.4B | ||
| Q2 25 | $875.5M | $7.6B | ||
| Q1 25 | $988.1M | $7.6B | ||
| Q4 24 | $1.0B | $7.7B | ||
| Q3 24 | $1.1B | $7.9B | ||
| Q2 24 | $1.1B | $7.9B | ||
| Q1 24 | $1.2B | $7.8B |
总资产ACDCRVTY
| Q4 25 | $2.6B | $12.2B | ||
| Q3 25 | $2.7B | $12.1B | ||
| Q2 25 | $2.8B | $12.4B | ||
| Q1 25 | $3.0B | $12.4B | ||
| Q4 24 | $3.0B | $12.4B | ||
| Q3 24 | $3.1B | $12.8B | ||
| Q2 24 | $3.2B | $13.4B | ||
| Q1 24 | $3.0B | $13.4B |
负债/权益比ACDCRVTY
| Q4 25 | 1.16× | — | ||
| Q3 25 | 1.05× | — | ||
| Q2 25 | 1.08× | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 0.93× | — | ||
| Q3 24 | 0.90× | — | ||
| Q2 24 | 0.88× | — | ||
| Q1 24 | 0.74× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $49.5M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $12.9M | $161.8M |
| 自由现金流率自由现金流/营收 | 3.0% | 21.0% |
| 资本支出强度资本支出/营收 | 8.4% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $19.6M | $509.4M |
8季度趋势，按日历期对齐
经营现金流ACDCRVTY
| Q4 25 | $49.5M | $182.0M | ||
| Q3 25 | $900.0K | $138.5M | ||
| Q2 25 | $100.4M | $134.3M | ||
| Q1 25 | $38.7M | $128.2M | ||
| Q4 24 | $76.5M | $174.2M | ||
| Q3 24 | $98.2M | $147.9M | ||
| Q2 24 | $113.5M | $158.6M | ||
| Q1 24 | $79.1M | $147.6M |
自由现金流ACDCRVTY
| Q4 25 | $12.9M | $161.8M | ||
| Q3 25 | $-33.4M | $120.0M | ||
| Q2 25 | $53.9M | $115.5M | ||
| Q1 25 | $-13.8M | $112.2M | ||
| Q4 24 | $13.3M | $149.8M | ||
| Q3 24 | $28.2M | $125.6M | ||
| Q2 24 | $51.6M | $136.6M | ||
| Q1 24 | $19.2M | $129.7M |
自由现金流率ACDCRVTY
| Q4 25 | 3.0% | 21.0% | ||
| Q3 25 | -8.3% | 17.2% | ||
| Q2 25 | 10.7% | 16.0% | ||
| Q1 25 | -2.3% | 16.9% | ||
| Q4 24 | 2.9% | 20.5% | ||
| Q3 24 | 4.9% | 18.4% | ||
| Q2 24 | 8.9% | 19.7% | ||
| Q1 24 | 3.3% | 20.0% |
资本支出强度ACDCRVTY
| Q4 25 | 8.4% | 2.6% | ||
| Q3 25 | 8.5% | 2.6% | ||
| Q2 25 | 9.3% | 2.6% | ||
| Q1 25 | 8.7% | 2.4% | ||
| Q4 24 | 13.9% | 3.4% | ||
| Q3 24 | 12.2% | 3.3% | ||
| Q2 24 | 10.7% | 3.2% | ||
| Q1 24 | 10.3% | 2.7% |
现金转化率ACDCRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | 43.94× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACDC
| Services | $385.6M | 88% |
| Products | $50.9M | 12% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
